Dissertations / Theses on the topic 'Real rank'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 20 dissertations / theses for your research on the topic 'Real rank.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.
Kachkovskiy, Ilya. "Almost commuting elements of real rank zero C*-algebras." Thesis, King's College London (University of London), 2013. https://kclpure.kcl.ac.uk/portal/en/theses/almost-commuting-elements-of-real-rank-zero-calgebras(1c891b23-dba5-4395-99dc-2884cbeb3bfb).html.
Full textStevens, Irina. "Hereditary subalgebras of certain simple non real rank zero C§*-algebras." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1998. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape11/PQDD_0011/NQ41511.pdf.
Full textFriis, Peter. "Normal elements with finite spectrum in C*-algebras of real rank zero." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape9/PQDD_0018/NQ45737.pdf.
Full textMoseley, P. G. "On the dimensions of linear spaces of real matrices of fixed rank." Thesis, University of Edinburgh, 1997. http://hdl.handle.net/1842/11860.
Full textKnauss, Lisa Monika [Verfasser], Peter [Gutachter] Heinzner, and Alan T. [Gutachter] Huckleberry. "Spherical algebraic subalgebras of real simple Lie algebras of rank 1 / Lisa Monika Knauss ; Gutachter: Peter Heinzner, Alan T. Huckleberry." Bochum : Ruhr-Universität Bochum, 2016. http://d-nb.info/1123283273/34.
Full textAnderson, Jonathan D. "Semi Autonomous Vehicle Intelligence: Real Time Target Tracking For Vision Guided Autonomous Vehicles." Diss., CLICK HERE for online access, 2007. http://contentdm.lib.byu.edu/ETD/image/etd1750.pdf.
Full textCarraturo, Massimo [Verfasser], Ernst [Akademischer Betreuer] Rank, Alessandro [Akademischer Betreuer] Reali, Michele [Gutachter] Chiumenti, Ernst [Gutachter] Rank, and Alessandro [Gutachter] Reali. "Modelling, Validation, and Design for Additive Manufacturing : Applications of numerical methods to 3D printing processes / Massimo Carraturo ; Gutachter: Michele Chiumenti, Ernst Rank, Alessandro Reali ; Ernst Rank, Alessandro Reali." München : Universitätsbibliothek der TU München, 2020. http://d-nb.info/1223093190/34.
Full textWan, Ariffin Wan Nur Suryani Firuz. "Real-time resource management and energy trading for green cloud-RAN." Thesis, King's College London (University of London), 2017. https://kclpure.kcl.ac.uk/portal/en/theses/realtime-resource-management-and-energy-trading-for-green-cloudran(b576b0a7-0aa3-425e-9b77-407dba2bb6f2).html.
Full textZander, Nils Dietrich [Verfasser], Ernst [Akademischer Betreuer] [Gutachter] Rank, Alessandro [Gutachter] Reali, and Zohar [Gutachter] Yosibash. "Multi-level hp-FEM: dynamically changing high-order mesh refinement with arbitrary hanging nodes / Nils Dietrich Zander ; Gutachter: Alessandro Reali, Ernst Rank, Zohar Yosibash ; Betreuer: Ernst Rank." München : Universitätsbibliothek der TU München, 2017. http://d-nb.info/1131253752/34.
Full textSehgal, Anuj. "Investigating the development and function of M cells." Thesis, University of Edinburgh, 2017. http://hdl.handle.net/1842/28738.
Full textDelisle, Steve. "Read my gorget transformations in the utility of gorgets in North America from insignia of rank to symbols of diplomacy and presentation objects and the enigma of the "Otsiquette Gorget" /." Access to citation, abstract and download form provided by ProQuest Information and Learning Company; downloadable PDF file, 434 p, 2008. http://proquest.umi.com/pqdweb?did=1654489001&sid=8&Fmt=2&clientId=8331&RQT=309&VName=PQD.
Full textPredrag, Filipov. "Uticaj različitih antitromboznih lekova na prevenciju nastanka rane tromboze arteriovenskih fistula za hemodijalizu kod bolesnika sa terminalnom bubrežnom insuficijencijom." Phd thesis, Univerzitet u Novom Sadu, Medicinski fakultet u Novom Sadu, 2017. http://www.cris.uns.ac.rs/record.jsf?recordId=104107&source=NDLTD&language=en.
Full textINTRODUCTION: Complications in end stage renal disease (ESRD) when the glomerular filtration rate (GFR) decreases below 10mL/min can only be treated by chronic dialysis or kidney transplant ie. total or partial renal replacement therapy. With prompt education of the patient regarding the progressive course of the chronic kidney disease, possibilities of dialysis treatment and kidney transplantation, the patient should timely be granted permanent functional vascular hemodialysis (HD) access through surgical intervention by creating arteriovenous fistula (AVF), preferably at least 6 months prior to the anticipated start of HD, as period for its maturation is between 4 and 6 weeks. Primary AVF is the generally best recommended permanent vascular access for patients planned for dialysis. The most common reason for dysfunction of the vascular access for hemodialysis are thrombotic complications in 80% of the cases, 90% of which appear in the venous segment of AVF as the consequence of progressive venous neointimal hyperplasia. Beside the histological characteristics of the venous blood vessel wall and hemodynamic conditions, in the etiopathogenesis of this “adaptive answer”, endothel and other components of the hemostatic system (platelet, coagulation and fibrinolysis), immunological and cytological components as well as genetic factors play a very important role. Prevention of occurrence of early thrombosis of vascular access for hemodialysis in patients with ESRD is possible by treatment with antithrombotic drugs, ie. antiplatelet or anticoagulant therapy. OBJECTIVE: Estimate the efficiency of applied antithrombotic drugs (ticlopidine and nadroparincalcium) in prevention of occurrence of early thrombosis/dysfunction of AVF for hemodialysis during its time of maturation within the 6 week period. Examine the level of biomarkers of the hemostatic system and thrombophilic markers in patients with ESRD before the creation of AVF with the goal of finding additional causes of occurrence of early thrombosis/dysfunction of arteriovenous fistula for hemodialysis. Determine the incidence of thrombophilia and its impact on the functionality of AVF and compare the efficiency of applied preventive regimen between patients with and without thrombophilia. MATERIAL AND METHODS: The study included persons of both sexes with previously established diagnosis of ESRD in which there were no contraindications for the planned surgical creation of the first permanent vascular access for hemodialysis in the form of autologous arteriovenous fistula (AAVF). After the surgical creation of the radiocephalic arteriovenous fistula in the distal third of the forearm of the non-dominant hand (89/121), intermedial (4/121) or proximal (28/121) AAVF, the total number of 121 patients were included in the study and divided into three groups in order to estimate the influence of different antithrombotic drugs in prevention of early thrombosis for hemodialysis in patients with ESRD: Group I, control; 40 subjects which did not receive antithrombotic therapy after the creation of AVF, Group II; 42 subjects which started receiving an antithrombotic drug from the tienopiridine group, Ticlodix® (ticlopidine) 2 x ½ of 250mg tbl, daily, during the period of 6 weeks, after the creation of AVF, and Group III; 39 subjects which started subcutaneously receiving a drug from the low-molecular weight herapin group, Fraxiparine® (nadroparine-calcium) 2850 anti Xa i.j. (0.3 ml) daily, during the period of 6 weeks. One-time determination of laboratory parameters and renal function, glucose metabolism and chronic inflammation, hemostatic system functionality, thrombophilic markers and gene polymorphism was performed within two weeks prior to surgical creation of AAVF. The criteria for determining the outcome of the impact of antithrombotic therapy is the maturation of AVF, which is defined as successful if the implementation of effective hemodialysis started at least 6 weeks after its creation, where the effectiveness of hemodialysis is estimated by a competent nephrologist. The diagnosis of the presence of AVF thrombosis was set by a competent vascular surgeon/nephrologist through physical examination during its maturation, which included inspection, palpatory determination of absence of the characteristic thrill and auscultatory characteristics of the flow of AVF, or by ultrasonographic examination by the radiologist. RESULTS: Between the groups in terms of number of thrombosed/dysfunctional AVF during its maturation (12/40 vs. 4/42 vs. 5/39, P = 0.033), a significant statistical difference was established, as well as by comparing the number of thrombosed/dysfunctional AVF during maturation in the control group compared to the group of respondents (unified Group II and Group III) which received antithrombotic prophylaxis (12/40 vs. 9/81, P = 0.009). Through further analysis of the examined groups, a statistically significant difference was observed in the number of thrombosed/dysfunctional AV fistula between the control Group I and Group II (P = 0.019). There was no statistically significant difference noticed in the numbers of thrombosed/dysfunctional AVF between the subjects in the control Group I and Group III, as well as between Group II and Group III. Presence of the number of thrombosed/dysfunctional distal AVF during their maturation (12/33 vs 2/31 vs. 3/24, P = 0.008) between the groups statistically significantly varied, as well as the presence of the number of thrombosed/dysfunctional distal AVF during the maturation in the control group as compared to the group of subjects who received antithrombotic prophylaxis (12/34 vs. 5/55; P=0.002). By testing statistical differences in the number of thrombosed/dysfunctional distal AVF between the subjects in the control Group I and Group II a statistically significant difference (P = 0.005) was established, while there was no statistically significant difference between Group I and Group III (P = 0.051), nor between Group II and Group III (P = 0.439). Among the subgroup of patients with thrombosis/dysfunction of AVF 21/121 (17.35%) and the subgroup of subjects with functionally maturated AVF 90/121 (82.64%), a statistically significant difference of the examined hemostasis parameters was present in the values of platelet aggregation with collagen as the inducer (59.33 ± 75.04 vs. 33.1 ± 29.6; P = 0.033). A significant statistical difference was recorded in the presence of the following thrombophilic markers: deficit of PC (3/21 vs. 3/100; P = 0.030), APC-R (4/21 vs. 5/100; P = 0.026), the presence of antiphospholipid ACL IgM antibodies ( 1/21 vs. 0/100; P = 0.028), heterozygous FV G1691A polymorphism (3/21 vs. 3/100; P = 0.03) and homozygous gene mutation FII G20210A (1/21 vs. 0/100; P = 0.028), between the subgroups of patients with thrombosed/dysfunctional and functional AVF. There also was a significant statistical difference between the groups of patients which encountered thrombosis/dysfunction of AVF and subgroups of subjects with functional maturated AVF in relation to the existence of previous thrombosis (23/21 vs. 19/100; P = 0.000) and the presence of isolated venous thrombosis (9/21 vs. 2/100; P = 0.000). Predictive potential of individual parameters for AVF maturation was tested by univariate logistic regression analysis. During the examination of the influence of individual parameters on fistula maturation, we observed that subjects who received antithrombotic therapy were 3 times more likely to develop functionally maturated AVF [OR 3.45 (1.3-9.03)] as compared to subjects who did not receive any treatment. Subjects which previously had thrombosis had a multiple times increased risk [OR 6.92 (2:51 to 19:06)] of developing thrombosis/dysfunctional AVF during its maturation. When examining the influence of individual parameters on the risk of thrombosis/dysfunction of the distal AVF, we noted that the implementation of antithrombotic therapy [OR 5.4 (CI 1.7 - 17:35)] reduced risk of thrombosis/dysfunction of the distal AVF by five times, ie. that the implementation of antithrombotic therapy increases the chance for adequate distal AVF maturation by five times. The subjects that had atherosclerotic cardiovascular diseases (CVD) [OR 0.32 (0.1-0.98)] or previous thrombosis [OR 0.14 (0.04-00.44)] had a 68% or 86% less chance for adequate distal AVF maturation (334). Thrombophilia was present in 59/121 (48.8%) patients. In relation to the markers of activation of coagulation components of the hemostatic system and inflammatory markers, among subgroups of subjects with or without thrombophilia a statistically significant difference was present in the FVIII concentration (170.35 ± 103.97 vs. 235.26 ± 124.80; P = 0.02) and the platelets/lymphocytes ratio (181 ± 64.58 vs. 148.11 ± 66.15; P = 0.026). In relation to the localization of AVF, in the subgroup of subjects with thrombophilia and thrombosed/dysfunctional AVF, 8/11 of them belonged to distal AVF, 3/11 proximal AVF, while in the subgroup of subjects without thrombophilia and thrombosed/dysfunctional AVF, had 9/10 distal and 1/10 proximal AVF. In the group of subjects with thrombophilia there was no record of the presence of statistically significant differences in the efficiency of antithrombotic regimen which was measured by the frequency of thrombosis/dysfunction of AVF as compared to subjects with thrombophilia which did not receive antithrombotic therapy (5/19 vs. 2/18 vs. 4/22, P = 0.493). In the group of subjects without thrombophilia statistically significant differences were found in the frequency of thrombosis/dysfunctions of AVF among groups with and without the use of antithrombotic drugs in the total number of thrombosed/dysfunctional AVF (7/21 vs. 2/24 vs. 1/17, P = 0.030). Although the presence of thrombosis/dysfunction of AVF in patients with combined thrombophilia was more frequent compared to those who had other types of, or did not have thrombophilia (6/18 vs. 15/103; P = 0.052), it did not reach a statistically significant value. CONCLUSION: Prophylactic use of antithrombotic drugs (ticlopidine and nadroparin-calcium) reduces the incidence of early thrombosis and the occurrence of primary AVF dysfunction for hemodialysis during its maturation. Implementation of antithrombotic therapy reduced risk of thrombosis/ dysfunction of the distal AVF during its maturation by five times. Patients who have had previous thrombosis have multiple times greater risk of AVF thrombosis during its maturation. In patients who had atherosclerotic CVD or previous thrombosis, the probability for adequate maturation of distal AVF is lower by 68% or 86%. In our study there was no evidence of superiority of anticoagulant compared to antiplatelet prophylaxis ie. both regimens were equally effective. In ESRD there is significant disarrangement of hemostatic system functionality, which is reflected in endothelial dysfunction and disturbed (reduced) platelet functionality, the presence of procoagulant condition that is manifested by elevated thrombin activity, increased levels of clotting factors and reduced fibrinolytic activity. More frequent presence of total previous thrombosis (arterial and venous), higher frequency of isolated venous thrombosis and frequent presence of thrombophilia presented by the deficit of PC, the presence of resistance to APC, presence of anticardiolipin antiphospholipid antibodies IgM, heterozygous FV G1691A polymorphism, homozygous mutation FII G201210A and lower value of collagen induced platelet aggregation are the markers in our study which are significantly more frequent in patients with thrombosis/dysfunction of AVF for hemodialysis during its maturation. Thrombophilia is present in 48.8% of patients with ESRD, however our study does not determine its impact on early thrombosis/dysfunction of AVF except in the group of patients with combined thrombophilia. A small number of bleeding complications in our study points to the safety of the applied preventive regimen. Based on the obtained results, prophylactic use of ticlopidine or nadroparin-calcium in preventive doses can be recommended for patients with ESRD immediately after AVF creation. Prophylactic treatment of thrombotic complications in patients with newly created AVF is recommended especially in patients who have had previous thrombosis and/or clinical manifestations of atherosclerotic cardiovascular diseases.
MACCIONI, MAURO. "Tensor rank and eigenvectors." Doctoral thesis, 2017. http://hdl.handle.net/2158/1077336.
Full text"C*-algebras of real rank zero." Chinese University of Hong Kong, 1996. http://library.cuhk.edu.hk/record=b5888939.
Full textThesis (M.Phil.)--Chinese University of Hong Kong, 1996.
Includes bibliographical references (leaves 53-54).
Introduction --- p.2
Chapter 1 --- Preliminaries --- p.3
Chapter 1.1 --- A Summary on C*-algebras --- p.3
Chapter 1.2 --- Hereditary C*-subalgebras --- p.5
Chapter 1.3 --- C*-Inductive Limit --- p.7
Chapter 1.4 --- Basic K-Theory of C*-algebras --- p.9
Chapter 2 --- C*-algebras of Real Rank Zero --- p.14
Chapter 2.1 --- Basic Properties of C*-algebras with Real Rank Zero --- p.14
Chapter 2.2 --- Strongly Morita Equivalence and Extensions --- p.30
Chapter 3 --- Simple C*-algebras --- p.42
Chapter 3.1 --- Basic Properties --- p.42
Chapter 3.2 --- Cuntz Algebras --- p.51
Bibliography --- p.53
Ondrus, Alexander A. "Minimal anisotropic groups of higher real rank." Phd thesis, 2010. http://hdl.handle.net/10048/1001.
Full textTitle from pdf file main screen (viewed on June 24, 2010). A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Mathematics, [Department of] Mathematical and Statistical Sciences, University of Alberta. Includes bibliographical references.
BANCHI, MAURIZIO. "Typical Ranks of ternary cubic forms over R." Doctoral thesis, 2013. http://hdl.handle.net/2158/808076.
Full textVan, der Merwe Dirk 1964. "Pointing out of crime scenes : a technique used to link a suspect with a crime." Diss., 2008. http://hdl.handle.net/10500/2892.
Full textPolice Practice
M. Tech. (Forensic Investigation)
Marona, Paulina. "Rola białka MCPIP1 w procesach wzrostu, unaczynienia i progresji nowotworowej jasnokomórkowego raka nerki." Praca doktorska, 2021. https://ruj.uj.edu.pl/xmlui/handle/item/290873.
Full textEvery year, kidney cancers affect nearly 300 000 people, and 120 000 die of this disease. The most common type is clear cell renal cell carcinoma (ccRCC) which comprises 80% of all cases. Due to the lack of typical symptoms in the first stages, at the time of diagnosis, metastases are found in one-third of patients, and the chances of survival are dramatically reduced. Currently, the most commonly used treatment is tumor excision with partial or total nefrectomy, followed by chemo- or radiotherapy, which are associated with numerous side effects. Due to high level of tumor vasculature, therapy of more advanced stages of ccRCC is based on new antiangiogenic drugs, which inhibit multiple tyrosine kinase receptors such as VEGFR or PDGFR. Treatment with small molecules showed in approximately 38% of patients significant tumor control. However, despite of the efficacy of therapy, ccRCC often develops drug resistance, and the majority of patients who receive such treatment exhibit progressive disease after one year. Formation of new blood vessels is a critical step during tumorigenesis and metastatic spread. ccRCC develops highly vascularized tumors due to common mutation in von Hippel-Lindau gene and overexpression of proangiogenic factors. The ccRCC ability to leave primary site, active migration and settle in distant organs, is orchestrated by many factors such as angiogenesis, presence of immune cells and acquisition of the properties of more aggressive, mesenchymal phenotype. C-Met receptor plays an important role in both angiogenesis and epithelial to mesenchymal transition. It stimulates proliferation, inhibits apoptosis and regulates a number of factors responsible for metastasis. Inflammatory processes play a significant role in ccRCC growth and development. One of the negative modulators of the inflammatory response is the MCPIP1 protein, encoded by the ZC3H12A gene. MCPIP1 acts as an endonuclease due to RNase activity, which allows degradation of mRNA coding proinflammatory cytokines. Recent reports suggests that the MCPIP1 protein may significantly affect tumor development through direct or indirect regulation of factors involved in the processes of growth, proliferation or cell death. Moreover, it has been shown that MCPIP1 affects expression of proangiogenic factors such as VEGF or HIFs, and its level in tumor is lower than in adjacent healthy tissue. The main aim of doctoral dissertation research was to determine the role of MCPIP1 protein in the processes of growth, vascularization and progression of clear cell renal cell carcinoma, as well as its effect on acquiring resistance to targeted drugs sunitinib and sorafenib. In the first stage of the study, Caki-1 and Caki-2 cell lines with downregulation of MCPIP1 protein, as well as with stable overexpression of the wild type MCPIP1 and mutation in PIN domain which completely abolishes endonuclease activity were used. The following work demonstrates that low level of MCPIP1 or inhibition of its RNase activity lead to an increase in the proliferative potential of tumor cells and tumor growth in vivo. In addition, lack of MCPIP1 protein increases the number of functional blood vessels compared to control. In contrast, overexpression of the MCPIP1 slows tumor growth and reduces vascularization in vivo. Conducted experiments showed that activation of endothelial cells depends on the level of MCPIP1 protein in cancer cells. Both, inhibition and mutation of MCPIP1 in ccRCC increased secretion of proangiogenic factors such as IL-6, IL-8 and VEGF compared to control or MCPIP1 overexpressed cells. In consequence, this leads to internalization of VE-cadherin, relaxation of cell-cell junctions and activation of endothelial cells migratory potential. Concominantly, MCPIP1 level affects the expression of CXCR4, SDF-1 and c-Met genes, which are responsible for cell division and metastasis. Importantly, MCPIP1 overexpression reduces the number of lung micrometastases and inhibits the EMT process. Further analysis of clinical samples of patients at various stages of ccRCC, has shown that MCPIP1 protein level decreases with cancer progression. Furthermore, the level of c-Met receptor and other factors involved in cancer progression increase with successive stages of the disease. In the last part of the study, it was observed that therapy with small molecules such as sunitinib and sorafenib increases the aggressiveness of cancer cells and amount of lung metastases. Moreover, elevated phosphorylation of c-Met receptor with simultaneous decrease in the level of MCPIP1 may be a potential mechanism of resistance to sunitinib and sorafenib treatment. In summary, the MCPIP1 protein can be one of the factors modulating tumor development and marker of ccRCC progression. MCPIP1 controls cell proliferation, migration and secretion of proangiogenic factors. Furthermore, dependent regulation of MCPIP1 protein and c-Met receptor and their effect on drug resistance has been proven during research. Considering the results presented in this dissertation and published by other researchers, it is plausible that MCPIP1 may act as universal tumor suppressor.
Schubert, Antje. "Einfluss von GnRH Analoga auf die Metastasierung humaner Mammakarzinomzellen in vitro und in vivo." Doctoral thesis, 2010. http://hdl.handle.net/11858/00-1735-0000-0006-ADD9-6.
Full textMeiresonne, Frank Rogier. "Design of a novel bike lock." Master's thesis, 2021. http://hdl.handle.net/10400.8/6633.
Full text